Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

ConclusionsIn a real-world setting, pwRRMS on TRF and DMF had similar discontinuation rates over 24 months. Male pwRRMS on DMF with a previous history of therapeutic failure are at more risk of discontinuation therapy.
Source: Journal of Neurology - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 30 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): R.D. Russell, L.J. Black, N.M. Pham, A. Begley
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: August 2020Source: Multiple Sclerosis and Related Disorders, Volume 43Author(s): Amgad Droby, Lazar Fleysher, Maria Petracca, Kornelius Podranski, Junqian Xu, Michelle Fabian, Malgorzata Marjańska, Matilde Inglese
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 29 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Helena Beatriz Ferreira, Bruna Neves, Inês M. Guerra, Ana Moreira, Tânia Melo, Artur Paiva, M. Rosário Domingues
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
CONCLUSION: On the basis of a broadly based research and participatory development process, a set of indicators has been developed that enables comprehensive evaluation of the regional quality of care of cross-indication, integrated care models focusing on common diseases. In order to be able to increasingly evaluate aspects of care coordination and patient orientation, health promotion as well as nursing, palliative and emergency care in the future, it would be helpful if routine data were collected or made accessible in these areas as well. PMID: 32467041 [PubMed - as supplied by publisher]
Source: Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen - Category: Health Management Tags: Z Evid Fortbild Qual Gesundhwes Source Type: research
TRIUMPHANT, a new placebo-controlled trial, has not shown any benefit over placebo of three different drugs commonly used to treat fatigue in patients with multiple sclerosis.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Conditions:   Multiple Sclerosis;   Menstrual Pain;   Anxiety;   Fatigue;   Neurologic Symptoms Interventions:   Other: pain;   Other: fatigue;   Other: anxiety;   Other: position sense;   Other: balance;   Other: dual task performance Sponsor:   Ankara Yildirim Beyazıt University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Multiple Sclerosis;   Traumatic Brain Injury Interventions:   Behavioral: Emotional Processing Training;   Behavioral: Placebo Control Sponsor:   Kessler Foundation Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Multiple Sclerosis;   Menstrual Pain;   Anxiety;   Fatigue;   Neurologic Symptoms Interventions:   Other: pain;   Other: fatigue;   Other: anxiety;   Other: position sense;   Other: balance;   Other: dual task performance Sponsor:   Ankara Yildirim Beyazıt University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 28 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Konstantin Balashov, Suhayl Dhib-Jalbut, Igor Rybinnik
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
FRIDAY, May 29, 2020 -- Air pollution may be an environmental risk factor for multiple sclerosis, according to a study presented May 22 at the European Academy of Neurology Virtual Congress. Roberto Bergamaschi, M.D., Ph.D., from the IRCCS Mondino...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Brain | Italy Health | Multiple Sclerosis | Neurology | Study